A phase III clinical trial data published May 2 in Cell Reports Medicine found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma.
A study published in JAMA Network Open found that an overweight or obese body mass index in early and middle adulthood is associated with increased risk for gastrointestinal cancer. The study also found that frequent aspirin use did not modify this increased risk in overweight and obese individuals.
A team, led by researchers at Baylor College of Medicine, reported in the Journal of Experimental & Clinical Cancer Research that silencing the gene p16, even though the DNA itself does not change, can drive colorectal cancer progression in animal models.
American Cancer Society researchers discovered both favorable and unfavorable changes in major cancer risk factors, preventive behaviors and services, and screenings in the United States during the COVID-19 pandemic, according to the Cancer Prevention & Early Detection Facts & Figures 2023-2024 report.
Rural women are six times more likely to get timely breast, cervical and colorectal cancer screening with remote outreach that involves interactive education and follow-up support by telephone, according to a new study.
Results from the multinational, pivotal phase III SUNLIGHT* clinical trial of Lonsurf (trifluridine/tipiracil), alone or in combination with bevacizumab, in refractory metastatic colorectal cancer (mCRC) showed a statistically significant and clinically meaningful improvements in overall survival and progression-free survival for patients with refractory mCRC following disease progression or intolerance on two prior chemotherapy regimens compared to trifluridine/tipiracil alone.
The phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55), which evaluated the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer who have received one to three prior lines of therapy, demonstrated statistically significant improvements in progression free survival, overall response rate, and overall survival compared to chemotherapy.
In a study published in Cancer Discovery, researchers from the Wistar Institute reported a key mechanism as to how p53 suppresses tumors. By comparing the mechanisms of wildtype and variant p53, the researchers discovered the mechanism by which p53 triggers immune function that, in turn, kills the tumor.
Researchers at Baylor College of Medicine and collaborating institutions have identified a strategy cancerous tumors use to remotely disrupt the development of an immune response that could stop their growth.
Approximately one-third of patients with non-small-cell lung cancer who were treated with the targeted therapy Lumakras (sotorasib) survived for at least two years after enrolling in a large clinical trial that evaluated the drug—significantly longer than what can be expected from patients treated with standard chemotherapy.
